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ABSTRACT The long-term efficacy of gene therapy using
bone marrow transplantation requires the engraftment of
genetically altered totipotent hematopoietic stem cells (THSCs).
Ex vivo expansion of corrected THSCs is one way to increase
the efficiency of the procedure. Similarly, selective in vivo
expansion of the therapeutic THSCs rather than the endog-
enous THSCs could favor the transplant. To test whether a
conferred proliferative advantage gene can facilitate the in
vitro and in vivo expansion ofhematopoietic stem cells, we have
generated transgenic mice expressing a truncated receptor for
the growth factor erythropoietin. These mice are phenotypi-
cally normal, but when treated in vivo with exogenous eryth-
ropoietin they exhibit a marked increase in multipotent,
clonogenic hematopoietic cells [colony-forming units in the
spleen (CFU-S) and CFUs that give rise to granulocytes,
erythroid cells, macrophages, and megakaryocytes within the
same colony (CFU-GEMM)] in comparison with the wild-type
mice. In addition, long-term in vitro culture of tEpoR trans-
genic bone marrow in the presence of erythropoietin induces
exponential expansion of trilineage hematopoietic stem cells
not seen with wild-type bone marrow. Thus, the truncated
erythropoietin receptor gene shows promise as a means for
obtaining cytokine-inducible hematopoietic stem cell prolif-
eration to facilitate the direct targeting of THSCs and to
provide a competitive repopulation advantage for transplanted
therapeutic stem cells.
Mutations affecting the progeny of totipotent hematopoietic
stem cells (THSCs) cause various diseases, including hemo-
globinopathies, thalassemias, and congenital immunodeficien-
cies. A desirable treatment of such heritable disorders would
be to transplant normal allogeneic cells into the patient or to
use gene therapy to correct the genetic defects in an appro-
priate autologous cell population. Bone marrow transplanta-
tion has been used as a means to achieve both of these ends.
The toxicities associated with allogeneic bone marrow trans-
plantation and the limited availability of histocompatible
allogeneic donors has restricted the use of this treatment for
heritable disorders. This in turn has lead to an increase in the
number of attempts to achieve gene therapy in autologous
stem cells, most often through retroviral vectors (1). Unfor-
tunately, the use of retroviruses for this purpose has been
hindered by poor long-term expression of exogenous genes,
immune responses to the viral vectors, and the difficulty of
transducing THSCs, which are both relatively rare in harvested
marrow and mitotically quiescent. Ideally, gene therapy for an
inherited disease would correct the endogenous mutant gene
in THSCs to produce a permanent cure. At present, homol-
ogous recombination is the only means of specifically correct-
ing mutant genes. Although this method has been used to
correct a sickle cell mutation in erythroleukemia cells (2), it
has not been used successfully with normal THSCs. Three
severe problems presently limit the possibility of achieving
therapeutic gene transduction by homologous recombination:
(i) the rarity of the desired target cells, the THSCs; (ii) the low
frequency of homologous recombination, in general; and (iii)
the difficulty of maintaining and expanding THSC clonally
either in vitro or in vivo. A possible way of overcoming some
of these problems is to incorporate sequences into the thera-
peutic vector that allow controlled proliferation of stem cells
in vitro. These same sequences might then also provide corrected
stem cells with a controlled proliferative advantage in vivo.
The present paper describes experiments aimed at testing
this concept by first generating animals in which a candidate
proliferative advantage sequence is present as a single copy
transgene (3) and by then testing the effects of the candidate
sequence on proliferation of hematopoietic stem cells in vitro
and in vivo. A truncated erythropoietin (epo) receptor
(tEpoR) gene (4, 5) was chosen for these tests because: (i) epo
receptors are not normally expressed in THSCs (6, 7); (ii)
THSC should be capable of transducing a proliferative signal
from this receptor without affecting subsequent differentiation
(8, 9); (iii) the truncated receptor shows increased sensitivity
to epo compared with the normal full-length receptor (4, 5);
and (iv) similar, but naturally occurring, tEpoR mutations in
humans generate benign erythroid proliferation without ma-
lignant transformation (10, 11).
Our tests show that multilineage hematopoietic cells in the
bone marrow (BM) of transgenic mice expressing the tEpoR
transgene do proliferate both in vivo and in vitro in response to
the cytokine epo. This transgene may thus prove useful in
facilitating the use of gene targeting and other methods of
genetic alteration for gene therapy.
MATERIALS AND METHODS
Generation of Transgenic Mice. A 1.2-kb KpnI fragment
from a cDNA plasmid (PXMIV) that encodes an epo receptor
with a carboxy-terminal, 91-aa truncation (a gift from Alan
D'Andrea; ref. 5) was used to make the targeting construct. A
4.3-kb EcoRI/SalI fragment (12) encompassing the human
3-actin promoter and a 200-bp NdeI/BamHI fragment (13)
containing the SV40 polyadenylylation addition sequences
were inserted together with the tEpoR cDNA into the EcoRI
site of the pMPN8 targeting vector previously described (14).
The resultant targeting construct (see Fig. 1, below) was then
introduced into E14TG2a embryonic stem cells so that ho-
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ropoietin; tEpoR, truncated epo receptor; HPRT, hypoxanthine-
guanine phosphoribosyl transferase; BM, bone marrow; LTBMC,
long-term BM culture; TNC, total nucleated cell; CFC, colony-
forming cell; BFU-E, burst-forming units-erythroid; CFU, colony-
forming unit; CFU-S, CFUs in the spleen; CFU-GEMM, CFUs that
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mologous recombination could incorporate the
gene into the hypoxanthine-guanine phosphoribosyl
ferase (HPRT) locus as previously described (3).
cells were selected in hypoxanthine/aminopterin/thymidine
medium, and the desired targeting event was
Southern blotting. Targeted cell lines were used
transgenic animals by blastocyst injection (15).
Phenotypic Analysis of Hematopoietic Cells. Wild-type
transgenic mice were either untreated or treated
peritoneal injections of epo (10 units/mouse, or units/
kg, three times per week). Serum epo levels
both before and after multiple treatments using
cially available radioimmunoassay kit (EPO-Trac
Incstar, Stillwater, MN). Peripheral blood collected
orbital puncture was analyzed by centrifugation
ocrits, by counting in a hemocytometer for white
counts, and by Wright-Giemsa-stained smears for
cell differential counts. Hemoglobin levels and
were measured by a Roche Cobas Helios hematology
(Roche Diagnostic Systems, Nutley, NJ). Erythropoietic
sponses to hemolysis were tested by intraperitoneal
60 or 90 mg/kg of phenylhydrazine. Wright-Giemsa-stained
BM"aspirate" smears were made from tibial
morphologic differential analyses. Total
(TNCs) harvested from femora were counted,
were resuspended in cytokine-containing methylcellulose
dium (M3430 from Stem Cell Technologies,
clonogenic assays of colony-forming cells (CFCs),
forming units-erythroid (BFU-E), and CFU-GEMM
scribed (16). Day 12 CFU-S were assayed in irradiated
by standard methods (17); sham-injected control
showed no endogenous spleen colony formation,
adequate irradiation.
Analysis of in Vitro Hematopoiesis. Dexter-type
BM cultures (LTBMCs; ref. 18) were established
tained both with and without epo supplementation
ml). Four separate experiments were performed,
taining two to four cultures per group, with the
femur being used for each individual culture.
harvested cell productions from the cultures
bined outputs of LTBMCs from female and
LTBMCs were scored by microscopic examination
numbers of hematopoietically active, cobblestone
(8 X 8 mm) squares. Cultures were fed weekly
removal of the nonadherent cells, which were
visually in a hemocytometer. LTBMC nonadherent
analyzed periodically by cytospin centrifugation
logic examination after Wright-Giemsa
RESULTS AND DISCUSSION
Generation of Transgenic Mice. Homologous
tion, as illustrated in Fig. 1, was used to generate
a single copy of the tEpoR transgene incorporated
X-linked locus coding for HPRT. The HPRT
as the site for the tEpoR transgene, because
constitutively and ubiquitously expressed in vivo.
reason, we used the human,B-actin promoter
tional regulation of tEpoR. The HPRT locus
advantage of allowing direct selection of targeted
stem cells. Transgenic animals expressing tEpoR
they are healthy, currently up to 2 years of age,
Analysis of Hematologic Parameters. Hematopoietic
from the tEpoR transgenic animals were initially
determine whether the transgene causes any
tivity to endogenous epo, which would likely
by benign erythrocytosis. Table 1 shows
(- epo), the hematocrits in the transgenic mice are indistin-
guishable from those in wild-type mice, indicating the absence
of any erythrocytosis. To determine whether transgenic ani-
b m i
P1 2 3
c - m tEpoR |neo
3 4 5 6789
4 5 6 789
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FIG. 1. Generation of a single copy transgene
HPRT locus. (a) The mutant HPRT target locus
E14TG2a (19) embryonic stem cells. (The broken
genomic sequences upstream of the deletion.)
construct used to allow homologous recombination,
crossed lines, between sequences in the mutant
locus and the targeting plasmid. (c) The modified
locus containing the tEpoR and neomycin
Numbers and the letter P represent HPRT
respectively. The deletion in the E14TG2a locus
brackets. The boxed tEpoR represents the tEpoR
human,B-actin promoter and SV40 polyadenylylation
quence. Neo, its promoter, and pol A are represented
Plasmid sequences are shown by the fine
mals can mount normal erythropoietic responses
lenged, we tested their responses after
induced hemolysis. As assessed by increases
reticulocyte counts, the responses in the transgenic
type animals were identical (data not shown).
spleen weights, BM, and peripheral blood total
WBC counts from wild-type and transgenic animals
significant differences (data not shown). Platelet
slightly lower in the transgenic animals (Table -
however, their BM megakaryocyte numbers
guishable from normal. Other BM parameters
differences between transgenic and wild-type
absence of externally administered epo include
total nuclear cells (Table 1, epo), percentage
(Table 1, epo), and total myeloid cells (Table -
Thus, the transgenic animals show no abnormal
Table 1. Comparison of epo effects on hematopoietic cells
-epo +epo
Hematocrits, %
wt 46.5 ± 0.70a 48.8 ± 0.98a
tg 45.2 ± 070b 48.2 ± 0.98"
Platelet counts,X1109/liter
wt 870 ± 28cd 1034 ± 59c
tg 629 ± 47de 1015 ±747
BM TNCs, X10-7/Ml
wt 3.50 .72f 5.22± 069fg
tg 3.7 0.73h 7.11± 067gh
BM, % myeloid
wt 62.5 1.3i 44.5 ±3.8i i
tg 63.7 ± 4.8 61.2 ± 2.6'
Total myeloid cells, X 10-7/Ml
wt 2.2k 2.3k
tg 2.41 4.4'
Total erythroid cells, X 107/Ml
wt 1.3m 2.9m
tg 1.3n 2.8n
Total myeloid cells were calculated as the product of TNCs and %
myeloid in BM. Total erythroid cells were calculated as the product of
TNCs and % erythroid (100 - % myeloid) in BM. wt, Wild-type; tg,
transgenic. aP = 0.038; bP = 0.010; cP = 0.040; dP = 0.001; eP =
0.002; fP = 0.013; gP = 0.0038; hp = 0.00001;ip = 0.0012; and iP =
0.0039. The difference between epo-treated and untreated is AM.
kAMwt = 0.1; IAMtg = 2.0; mAMwt 1.6; and nAMtg 1.5.
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activity in the presence of endogenous epo and respond
normally to an increased demand for erythrocytes.
Epo Effects on in Vivo Hematopoiesis. To compare the
effects of exogenous epo on in vivo hematopoiesis in transgenic
and wild-type mice, animals were treated for several weeks
with epo doses equivalent to therapeutic doses in humans.
In some ways the transgenic and wild-type animals were not
significantly different. Thus the transgenic animals and wild-
type animals had similar baseline serum epo levels (data not
shown), which increased to similar levels (6- to 7-fold) after
several 400-units/kg doses of epo, indicating that the metab-
olism of epo was not significantly altered by expression of the
tEpoR transgene. The elevations of hematocrits and platelet
counts in the transgenic and wild-type mice after treatment
with exogenous epo were indistinguishable (Table 1, + epo).
Peripheral WBC counts in both the wild-type and transgenic
animals were unchanged by the epo treatment (data not shown).
However, the epo-treated transgenic animals differed from
wild-type in several important ways. First (Table 1, + epo),
they had significantly greater (2-fold) increases in BM TNCs
compared with wild-type (3.4 x 107 cells versus 1.7 x 107
cells/ml), which demonstrates a greater level of epo-induced
expansion due to the presence of the transgene. Second, BM
differential counts revealed that the transgenic BM had sig-
nificant (2-fold) increases in myeloid cells (AMtg = 2.0 in Table
1), while the myeloid cells in the wild-type BM did not change
in response to exogenous epo (AMWt = 0.1 in Table 1). The
increase in myeloid cells seen only in the transgenic animals
when given exogenous epo is in addition to increases in
erythroid progenitors seen in both the transgenic and wild-
type BM (AMtg = 1.5 and AM,,t = 1.6, in Table 1). Thus, the
tEpoR gene results in a proliferation of nonerythroid precur-
sors in response to exogenous epo that is not seen in the
wild-type BM but does not affect the level of erythroid
response to exogenous epo.
The numbers of several categories of BM clonogenic cells
from epo-treated transgenic and wild-type animals are com-
pared in Table 2. The in vitro clonogenic cells assayed included
both committed progenitors and multipotent progenitors. The
committed progenitors counted were: (i) CFUs for granulo-
cytes, macrophages, or both, together called CFCs (16); and
(ii) BFU-E (20). The multipotent progenitors (CFU-GEMM)
were cells, colony forming units, that give rise to granulocytes,
erythroid cells, macrophages, and megakaryocytes within the
same colony (21). The BM cells that form colonies in the
spleens of irradiated mice after transplantation in vivo
(CFU-S; ref. 17), include, but are not restricted to, pluripotent
progenitors.
The numbers of committed progenitors (BFU-E and CFC)
were not significantly different in the two types of animals
(Table 2) with or without exogenous epo; however, both pluri-
and multipotent progenitors (CFU-S and CFU-GEMM) were
significantly increased in the BM of the epo-treated transgenic
animals compared with the wild-type mice (Table 2), with the
total increases in transgenic CFU-S and CFU-GEMM being
2.6- and 2.5-fold greater than in the wild-type animals (see
legend to Table 2).
The data presented in the two tables show that, in addition
to the normal erythropoietic response seen in both wild-type
and transgenic animals, multipotent progenitor cells in the
tEpoR transgenic BM show a proliferative response to exog-
enous epo not seen with wild-type BM. The occurrence of this
effect in cells that do not normally express epo receptors is not
surprising, since the epo receptor belongs to a family of
cytokine receptors which share signal transduction pathways-
e.g. JAK-STAT (22, 23) and ras-MAP kinase (24)-and since
THSC exhibit a proliferative response to other cytokines
within this family, such as interleukin 3 (7, 25).
We conclude that exogenous epo induces the in vivo expan-
sion of multipotent hematopoietic cells expressing the tEpoR
transgene.
Epo Effects on in Vitro Hematopoiesis. To determine
whether the tEpoR transgene allows proliferation of hemato-
poietic stem cells in vitro, we used a Dexter-type LTBMC (18)
system. (Dexter cultures permit the in vitro maintenance and
differentiation of hematopoietic stem cells within a supportive
stromal cell layer for weeks to months.) Figs. 2 and 3 present
comparisons between the LTBMCs from transgenic and wild-
type mice in the absence and presence of epo. In the absence
of epo, both wild-type and transgenic LTBMCs showed an
essentially steady production of nonadherent cells for the first
30 days, after which time production rapidly declined (Fig. 2).
Cell production had completely ceased by '80 days. Morpho-
logic analyses of the harvested nonadherent cells showed that
erythroid, megakaryocytic, and myeloid hematopoiesis oc-
curred initially, but within two weeks, cell production became
and remained mainly myeloid. Later, macrophages predomi-
nated. The decline and eventual cessation in hematopoiesis
Table 2. Comparison of epo effects on clonogenic cells
- epo + epo ACFU-GEMM ACFU-S
BFU-E, per 105 cells plated
wt 2.5 ± 0.76 1.0 ± 0.14
tg 2.5 ± 0.76 1.3 ± 0.32
CFCs, per 105 cells plated
wt 87.5 ± 6.5 68.0 ± 3.8
tg 62.0 ± 7.0 84.2 ± 8.8
CFU-GEMM, per 105 cells plated
wt 46.7 ± 7.2 54.2 ± 2.3a
tg 40.7 ± 2.1b 65.4 ± 3.4ab
CFU-S, per 104 cells injected
wt 6.2 ± 0.34c 7.7 ± 0.49ac
tg 5.1 ± 0.56d 9.1 ± 0.49ad
Total femoral BM CFUs
wt 118.4e 18.3f
tg 313.7e 45.7f
Effects of epo on numbers of wt and tg committed progenitors, BFU-E (20) and CFCs (16) and multi-
and pluripotential progenitors CFU-GEMM (21) and CFU-S (17). Calculations of epo-induced differ-
ential increases in total clonogenic cells, CFU-S and CFU-GEMM in tg were compared to wt BM.
Differential increases were calculated as follows for both tg and wt animals: ACFU = (no. colonies x
TNCS)epo-supplemented - (no. colonies X TNC)non-supplemented. wt, Wild-type; tg, transgenic. ap = 0.025;
bp = 0.0001; CP = 0.011; and dp = 0.000002. The relative increase (Atg/wt) was calculated by dividing
ACFUtg by ACFUwt. eAtg/wt = 2.6; and fAtg/wt = 2.5.
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'°- A supplemented transgenic cultures showed prolonged and ex-
ponentially increasing hematopoiesis with continued accumu-
_ itgl+ epo lation of nonadherent cells well after the other three groups
30- _ wV+ epo had ceased producing cells (Fig. 2A and B). The straight linetg·/no.0 1 statistically fitted to the logarithmic plot of the epo-treated,. --*- - itgfno~ epao vtransgenic culture data (open circles) corresponds to a dou-
20- -a-- wVnoepo bling time of -23 days extending over the full 120 days of
·r^°~culture. The total number of nonadherent cells that the
epo-supplemented transgenic cultures produce per week in-
10-. - creased "20-fold over this time period. This increasing cellular
output was accompanied by an increase in the size and number
cQ-"g^, a^B~~~~~~^? °of hematopoietically-active cobblestone areas, which became
0c
--- confluent in 40-70 days (Fig. 2C). No cobblestone areas were
o 20 40 60 80 detectable in the wild-type or transgenic cultures without epo
Days in Culture by 56 days or in the wild-type cultures with epo by 84 days. Thecobblestone areas in the epo-supplemented tEpoR transgenic
LTBMCs contained many easily visible megakaryocytes and
erythroid clusters, in addition to the myeloid cells normally
4 e seen in these areas. Morphologic analyses of nonadherent cellsIB~~~~ D DoA?^0^by cytospin preparations showed that the epo-supplemented
3 transgenic cultures, unlike the wild-type cultures, maintained
\_tg/ epo trilineage hematopoiesis for up to 140 days (Fig. 3 A-C),
2
epo although toward the end of this period, the percentage of*^S^-0--- wUtk epo myeloid cells had decreased significantly.
- ----- tg/noepo It is interesting that following prolonged culture in the
1 ---- wtIno epo presence of epo, the transgenic LTBMCs eventually shift their
0
\ TS^.cellular output toward the erythroid lineage, despite the initial
production of myeloid and megakaryocytic lineages in sub-
\1 /J ^^stantial amounts. This may be due in part to the differentiative-1-r- . ....,v** .--* function of the epo receptor. Different signal transduction
0 20 40 60 80 100 120 pathways are known to be responsible for apoptosis preven-
Days in Culture tion, proliferation, and differentiation in response to epo (23,24, 26). Conceivably, the balance between proliferation and
differentiation may be influenced by the relative numbers of
^50 C ^cytokine receptors (for example, interleukin 3 receptor, gran-OCp(c^ ^B ulocyte-macrophage colony-stimulating factor receptor, or
40|L __epo receptor) present on an individual cell; the relative
amounts of various cytokines in culture may also affect the
30 - H - balance. Thus it has been shown that erythroid development in
a multipotent cell line, FDCP-Mix A4, is affected by the
20 | relative concentrations of epo and interleukin 3 (27). It may
therefore be beneficial to limit the concentration of epo or the
10- duration of the supplementation to achieve maximal prolifer-
ation of THSC without excess stimulation of differentiation.
0- An important concern regarding the potential value of using
28 56 84 a proliferative advantage sequence is to ensure that it is not
associated with uncontrolled growth. We therefore tested theDays in Culture nonadherent cells from 110- to 140-day transgenic cultures for
m wt/no epo
-
tg/no epo J wv+ epo M tgt+ epo their ability to proliferate in the absence of growth-promoting
stroma and/or without epo, conditions under which trans-
Comparison of epo effects on wild-type and transgenic formed or factor-dependent cell lines can proliferate. None of
s. (A) Cumulative nonadherent TNC counts from wild-type these conditions sustained growth, indicating that neither the
sgenic LTBMCs from a representative experiment. (B) A plot selection of transformed cells nor the development of factor-
sted nonadherent cells from a different experiment. The dependent cell lines was responsible for the proliferation seen
d TNCs are plotted on a logarithmic scale to demonstrate that in the epo-supplemented transgenic LTBMCs. In addition, the
tial growth is occurring in transgenic LTBMCs supplemented intact transgenic animals never developed leukemia or clonal
The solid straight line is best fit for 7-110 days. (C) Total proliferation of any lineage, even when treated with epo for asone areas from the second experiment. long as 6-8 weeks.long as 6-8 weeks.
ad with the decline and disappearance of cobblestone These in vitro data consequently show that epo can induce
rig. 2C). The time course and types of cells produced an exponential but benign proliferation of cells of several
ned to those expected for Dexter-type cultures under lineages in tEpoR transgenic LTBMCs in a manner that is not
)nditions. Even when supplemented with epo, wild-type seen with the wild-type BM, most likely through a common
s still produced similar numbers and types of nonad- multipotent precursor. We cannot at present rigorously ex-
:ells over time, except for some persistence of erythroid clude the possibility that the proliferation of the cells respond-
ors for several weeks (Fig. 3 D and E). Thus, the ing to epo in the transgenic LTBMCs are committed progen-
nic LTBMCs without epo are virtually indistinguish- itors, but it should be noted that the prolonged production of
nonadherent cell production and morphology from nonadherent cells that we observe exceeds the known lifespan
)e LTBMCs, either with or without epo. of committed progenitors (<5 weeks). The LTBMC data
:ed differences were seen, however, when the trans- consequently suggest, although they do not prove, an epo-
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FIG. 3. Morphologic analyses of nonadherent cells from the LTBMCs. Cytospin preparations of nonadherent cells were stained with
Wright-Giemsa and examined at multiple times throughout the long-term culture period. Shown are representative photomicrographs (X400
magnification) from day 7 (A), day 56 (B), and day 140 (C) from transgenic epo-supplemented cultures and day 7 (D) and day 56 (E) from wild-type
epo-supplemented cultures; nonadherent cells were no longer present in wild-type cultures at 140 days. Erythroid precursors (e), neutrophils (n),
megakaryocytes (M), and macrophages (m) are as denoted.
ing the tEpoR transgene that is comparable to the expansion
demonstrated in vivo.
General Conclusions. Ex vivo expansion of hematopoietic
cells with cytokines has been used by previous investigators to
increase the efficiency of gene transfer and to amplify pro-
genitors, thereby facilitating the engraftment of donor cells
(28, 29). Although this strategy may result in several hundred-
fold expansions of clonogenic progenitor cells, increases in
earlier precursors are usually in the range of 2- to 8-fold. In
cultures of human cells, early pluripotent long-term culture
initiating cells may be expanded up to 50-fold (30) using this
approach, although long-term repopulating cells (THSC) have
been maintained for only short periods in vitro (31), with
minimal, if any, expansion.
Some recent data suggest that ex vivo expansion of stem cells
may compromise long-term engraftment (32), possibly by
inducing their differentiation. However, two recent studies
have been published (33-35) in which retrovirally-transduced
BM cells expressing epo receptors showed increases in early
progenitors (CFU-GEMM), similar to our observations, with-
out these cells becoming committed to erythroid differentia-
tion. Nevertheless, it may be more advantageous to facilitate
the use of autologous BM for gene therapy by generating the
controlled expansion of therapeutically modified THSC in
vivo, rather than in vitro.
The concept of conferring a proliferative advantage on stem
cells during therapy was first proposed in 1980 (36). At that
time, and subsequently (37-40), the concept was implemented
by increasing resistance to toxic agents. We have demonstrated
here that the benign cytokine epo can induce controlled
proliferation of multipotent stem cells expressing tEpoR. The
expansion of primitive progenitors (CFU-S and CFU-GEMM)
that we have seen in vivo in the epo-treated mice expressing
tEpoR is at present modest (-2.5-fold), but it does show that
the transgene can allow epo-induced proliferation of these
cells. The prolonged trilineage hematopoiesis seen in epo-
supplemented, transgenic LTBMCs suggests that stem cells
can also be amplified in vitro. The practical application of the
benefits of the tEpoR transgene requires further experiments
to show: (i) whether the transgene is effective when it is present
and expressed more specifically in THSC, the long-term
repopulating stem cells, and (ii) whether the advantage se-
quence will be effective when it is included in a therapeutic
construct. Subject to these limitations, the tEpoR gene shows
considerable promise for eventual use as a benign advantage
sequence in two contexts: it may allow the in vitro clonal
expansion of corrected stem cells, thereby facilitating targeted
or other genetic modifications of these cells, and it may provide
corrected, transplanted cells with a controllable competitive
proliferative advantage over uncorrected endogenous THSC
in vivo.
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